You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国疫苗协会料年底前新冠疫苗有望接种近七成国人 明年产能50亿剂
阿思达克 04-08 17:03
据《北京日报》报道,在由北京大学主办的「新冠疫苗与疫苗产业国际化」研讨会上,中国疫苗行业协会会长封多佳披露,明年中国新冠疫苗年产能将达到约50亿剂,而在今年底前近七成国人有望陆续进行接种。

封多佳则表示,截至目前,中国国产新冠疫苗在国内的使用量超过1.3亿剂,而出口数量也超过了1亿剂,涉及百余个国家。

科兴控股(香港)总经理杨光在会上介绍,目前科兴的疫苗年产能已达20亿剂,国内还有不少疫苗企业也在朝着年产能10亿乃至20亿剂规模迈进,中国疫苗产品和产业出海已站在更新的高度上,达到了更高的标准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account